Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matt Johnson

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Bioanalysis|January 25, 2020
Harnessing anti-idiotypic antibody alternatives to advance biotherapeutic pharmacokinetic assaysMatt Johnson
Photosynthesis Research|December 17, 2013
Photosynthesis and the environmentAsaph B Cousins, Matt Johnson, Andrew D B Leakey
Journal of Strength and Conditioning Research|October 10, 2018
Optimal Emotional Profiles for Peak Performance in Strength and ConditioningJonathan J Cooper, Matt Johnson, Jon Radcliffe, et al.
Biosensors & Bioelectronics|May 14, 2005
Detection of CFTR mutations using ARMS and low-density microarraysShannon Eaker, Matt Johnson, Josh Jenkins, et al.
International Journal of Sports Physical Therapy|June 30, 2011
A pilot study of core stability and athletic performance: is there a relationship?Chris Sharrock, Jarrod Cropper, Joel Mostad, et al.
Journal of Applied Clinical Medical Physics|June 24, 2015
Radiographic film dosimetry of proton beams for depth-dose constancy check and beam profile measurementInhwan J Yeo, Anthony Teran, Abiel Ghebremedhin, et al.
American Health & Drug Benefits|June 20, 2017
Multispecialty Rating of Evidence-Based Conditions for Intravenous Immunoglobulin Therapy Using a 3-Axis Prioritization AlgorithmJordan S Orange, Matt Johnson, Barb Lennert, et al.
Frontiers in Immunology|December 5, 2025
Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risksScott L Baughan, Timothy Folsom, Matt Johnson, et al.
Frontiers in Immunology|February 2, 2026
Correction: Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risksScott L Baughan, Timothy Folsom, Matt Johnson, et al.
Orphanet Journal of Rare Diseases|February 26, 2016
The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference NetworksTeresinha Evangelista, Victoria Hedley, Antonio Atalaia, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Bioanalysis|January 25, 2020
Harnessing anti-idiotypic antibody alternatives to advance biotherapeutic pharmacokinetic assaysMatt Johnson
Photosynthesis Research|December 17, 2013
Photosynthesis and the environmentAsaph B Cousins, Matt Johnson, Andrew D B Leakey
Journal of Strength and Conditioning Research|October 10, 2018
Optimal Emotional Profiles for Peak Performance in Strength and ConditioningJonathan J Cooper, Matt Johnson, Jon Radcliffe, et al.
Biosensors & Bioelectronics|May 14, 2005
Detection of CFTR mutations using ARMS and low-density microarraysShannon Eaker, Matt Johnson, Josh Jenkins, et al.
International Journal of Sports Physical Therapy|June 30, 2011
A pilot study of core stability and athletic performance: is there a relationship?Chris Sharrock, Jarrod Cropper, Joel Mostad, et al.
Journal of Applied Clinical Medical Physics|June 24, 2015
Radiographic film dosimetry of proton beams for depth-dose constancy check and beam profile measurementInhwan J Yeo, Anthony Teran, Abiel Ghebremedhin, et al.
American Health & Drug Benefits|June 20, 2017
Multispecialty Rating of Evidence-Based Conditions for Intravenous Immunoglobulin Therapy Using a 3-Axis Prioritization AlgorithmJordan S Orange, Matt Johnson, Barb Lennert, et al.
Frontiers in Immunology|December 5, 2025
Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risksScott L Baughan, Timothy Folsom, Matt Johnson, et al.
Frontiers in Immunology|February 2, 2026
Correction: Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risksScott L Baughan, Timothy Folsom, Matt Johnson, et al.
Orphanet Journal of Rare Diseases|February 26, 2016
The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference NetworksTeresinha Evangelista, Victoria Hedley, Antonio Atalaia, et al.
Pageof 3